Structure Therapeutics (GPCR) Financials

Here’s a concise, investor-focused read on Structure Therapeutics (GPCR) using the four most recent years of quarterly income, cash flow, and balance sheet data provided. The company appears to be in a pre-commercial phase, with liquidity largely supported by equity financing and a recent quarterly return to profitability in Q4 2025, alongside ongoing operating expenses and share dilution dynamics.

• In Q4 2025, net income from continuing operations was about $33.0 million, with basic earnings per share around $0.20, marking a positive quarterly result after a stretch of losses.
• A sizable equity raise occurred in Q4 2025: issuance of common equity around $703 million, significantly boosting liquidity to fund ongoing operations and development.
• The balance sheet shows a solid capital base, with total equity in the mid-to-high $700 million range across mid-2025 quarters (roughly $0.77 billion), indicating ample shareholder support.
• Cash and equivalents remained robust through 2025, with roughly $103 million in Q3 2025 and around $152 million in Q1 2025, providing a meaningful liquidity runway.
• Total assets remained substantial (about $0.83 billion in Q3 2025), with a cash cushion relative to liabilities, suggesting strong capitalization while R&D investments continue.
• Revenue remains effectively non-existent in the periods shown, highlighting the company’s ongoing development stage and lack of commercial sales.
• R&D expense is consistently the largest operating cost driver (frequently in the high tens of millions per quarter), underscoring the company’s focus on pipeline programs and discovery work.
• Operating cash flow shows persistent cash burn in several quarters, with negative net cash from continuing operating activities in multiple periods (for example, around -$64.4 million in Q4 2025 and negative amounts in Q3 and Q2 2025).
• Dilution-related pressure exists: diluted earnings per share are negative in several quarters despite some positive net income, reflecting the impact of equity financing on per-share metrics.
• There is a notable reliance on financing activities to fund liquidity, evidenced by large equity issuances that drive cash inflows and, consequently, share dilution risk for existing holders.